Fig. 5: Vaccine-induced antibody responses to ancestral Wuhan and other variants of concern (VOC).

Neutralizing antibody (% inhibition) against a Delta, c Omicron BA.1 and e BA.2 variants from S-N- [n = 7 for COVISHIELDTM (dark blue); n = 5 for COVAXIN® (dark red)] and S+ and/or N+ [n = 29 for COVISHIELDTM (teal), n = 31 for COVAXIN® (pink)] vaccinees measured in serum samples by MSD V-PLEX SARS-CoV-2 panel 25 (ACE2). Neutralizing antibody (% inhibition) against b Delta, d Omicron BA.1 and f BA.2 variants at baseline and 2 weeks post-vaccination in serum samples from the S+ and/or N+ group further segregated as N- (n = 15 for both COVISHIELDTM and COVAXIN®) and N+ (n = 14 for COVISHIELDTM and n = 16 for COVAXIN®). Line graphs represent antibody levels at baseline and 2 weeks post-vaccination. Assay cut-off values for each assay are denoted in purple and highest pre-pandemic cut-off in black. Two-way ANOVA with Šídák’s multiple comparisons test was used for statistical analysis.